<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.0" -->
<rss version="0.92">
<channel>
	<title>Exubera Inhaled Insulin: Reported &#038; Suspected Risks for Diabetics</title>
	<link>http://www.exubera-risks.com</link>
	<description>Exubera inhaled insulin news and information on the FDA approved diabetes drug</description>
	<lastBuildDate>Wed, 09 Apr 2008 21:28:08 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>Pfizer, Nektar: Diabetics Who Used Exubera Developed Lung Cancer</title>
		<description><![CDATA[This blog has continued researching and reporting on potential Exubera inhaled insulin risks for more than two years.
Pfizer&#8217;s and Nektar&#8217;s announcements this morning that  6 of the 4,740 patients using Exubera in clinical studies developed lung cancer confirms what this blogger has been saying all along:

That it was foolish of the FDA to rush [...]]]></description>
		<link>http://www.exubera-risks.com/2008/04/09/pfizer-nektar-diabetics-who-used-exubera-developed-lung-cancer/</link>
			</item>
	<item>
		<title>Pfizer Laying Off 660 Exubera Inhaled Insulin Workers From Terre Haute Plant</title>
		<description><![CDATA[Pfizer&#8217;s decision to halt Exubera inhaled insulin sales has led the layoff of 660 of the drug company&#8217;s workers at its Terre Haute, Indiana manufacturing facility.

The news was announced by Nat Ricciardi, president of Pfizer Global Manufacturing. Workers were informed that they would lose their jobs today, according to the Kalamazoo Gazette.
That will leave more [...]]]></description>
		<link>http://www.exubera-risks.com/2008/01/28/pfizer-laying-off-660-exubera-inhaled-insulin-workers-from-terre-haute-plant/</link>
			</item>
	<item>
		<title>Novo-Nordisk Opts to Stop Inhaled Insulin Development</title>
		<description><![CDATA[Danish diabetes drugmaker Novo-Nordisk has opted to halt further development of its AERx inhaled insulin.

The pharmaceutical company&#8217;s new decision comes shortly after it Pfizer and Novo settled their patent litigation of Pfizer&#8217;s Exubera inhaled insulin.
Novo&#8217;s AERX inhaled insulin was in Phase III trials when the decision was made.  The device previously that was previously [...]]]></description>
		<link>http://www.exubera-risks.com/2008/01/15/novo-nordisk-opts-to-stop-inhaled-insulin-development/</link>
			</item>
	<item>
		<title>Novo-Nordisk, Pfizer Settle Patent Lawsuit Over Inhaled Insulin</title>
		<description><![CDATA[Novo-Nordisk and Pfizer reportedly settled their patent litigation this week over Pfizer&#8217;s failed Exubera inhaled insulin and Novo&#8217;s AERx insulin that the Danish drugmaker has been developing with Aradigm Corp.

The litigation started just before Pfizer brought Exubera to market (after considerable delays), and continued for just over a year.
Novo claimed that Exubera infringed on a [...]]]></description>
		<link>http://www.exubera-risks.com/2007/12/16/novo-nordisk-pfizer-settle-patent-lawsuit-over-inhaled-insulin/</link>
			</item>
	<item>
		<title>Go Insulin Injectable Insulin Ads From Sanofi - Spending $1.3B in Exubera Deal Money</title>
		<description><![CDATA[After scoring a $1.3 billion deal selling Pfizer all of its rights to market Exubera inhaled insulin, Sanofi-Aventis probably laughed all the way to the bank when Pfizer pulled the ridiculously unprofitable diabetes drug from the market.
That&#8217;s why Sanofi&#8217;s latest ad campaign for injectable insulin has a timely &#8220;I told you so&#8221; quality to it. [...]]]></description>
		<link>http://www.exubera-risks.com/2007/11/29/go-insulin-injectable-insulin-ads-from-sanofi-spending-13b-in-exubera-deal-money/</link>
			</item>
	<item>
		<title>Alkeremes CEO Warns AIR Inhaled Insulin With Lilly May Affect Lung Function</title>
		<description><![CDATA[Less than a week after Pfizer decided to stop selling Exubera inhaled insulin, the Chairman of rival drug developer Alkermes cautioned that it&#8217;s AIR inhaled insulin could also affect diabetics&#8217; lung function.

Richard Pops, Chairman of Cambridge, Mass.-based Alkeremes, told Reuters that the inhaled insulin that the company is jointly developing with Eli Lilly &#038; Co., [...]]]></description>
		<link>http://www.exubera-risks.com/2007/10/23/alkeremes-ceo-warns-air-inhaled-insulin-with-lilly-may-affect-lung-function/</link>
			</item>
	<item>
		<title>Pfizer Stops Exubera Inhaled Insulin Sales, Citing Financial Reasons</title>
		<description><![CDATA[It&#8217;s official: Pfizer&#8217;s Exubera inhaled insulin experiment is over.
Sales of the diabetes drug were a complete failure. Some might even think of them as non-existent, considering that Pfizer paid Sanofi-Aventis $1.3 billion to acquire exclusive worldwide rights to market the insulin, yet only generated $4 million in sales for Q2 2007.   The company&#8217;s website [...]]]></description>
		<link>http://www.exubera-risks.com/2007/10/21/pfizer-stops-exubera-inhaled-insulin-sales-citing-financial-reasons/</link>
			</item>
	<item>
		<title>Apparent Pfizer Employee Discloses Exubera Production Issues</title>
		<description><![CDATA[One Pfizer employee recently disclosed alleged problems at Pfizer&#8217;s Exubera inhaled insulin manufacturing plant in Terre Haute, Inc.:

The person disclosed that:
&#8220;[T]here are several issues with [Exubera&#8217;s] manufacturing process&#8230;lets just say it&#8217;s not efficient or effective. As for the powder processing, they still have agreements with Nektar to produce a certain % of the powder used. [...]]]></description>
		<link>http://www.exubera-risks.com/2007/10/12/apparent-pfizer-employee-discloses-exubera-production-issues/</link>
			</item>
</channel>
</rss>
